Omnicell (OMCL) AI Stock Analysis

• Market Cap: $2.18B
• Dividend Yield: N/A
• Average Volume (3M): 383.31K
• Price to Earnings (P/E): 113.7
• Beta (1Y): 0.16
• Revenue Growth: 10.67%
• EPS Growth: N/A
• Country: US
• Employees: 3,620
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 0.51
• Shares Outstanding: 44,876,522
• 10 Day Avg. Volume: 302,171
• 30 Day Avg. Volume: 383,315
• PEG Ratio: -1.02
• Price to Book (P/B): 1.65
• Price to Sales (P/S): 1.84
• P/FCF Ratio: 13.55
• Enterprise Value/Market Cap: 1.04
• Enterprise Value/Revenue: 1.91
• Enterprise Value/Gross Profit: 4.37
• Enterprise Value/Ebitda: 19.15
• 1Y Price Target: $55.60
• Price Target Upside: 14.64% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 71 Outperform
• Price Target: $54.00 ▲(11.34% Upside)

Omnicell's overall stock score reflects a strong earnings call and positive corporate events, indicating strategic growth and innovation. However, high valuation and operational efficiency challenges temper the score. The technical analysis supports a bullish outlook, but caution is advised due to overvaluation risks.

Positive Factors

Recurring revenue mix

A diversified mix of hardware sales plus subscription software, maintenance and services supports more predictable revenue and cash flows. Over 2–6 months this recurring base increases customer lifetime value, smooths seasonality from equipment sales and funds platform investments.

Low leverage / balance sheet strength

Very low leverage (D/E ~0.16) gives Omnicell financial flexibility to fund R&D, M&A, or weather demand shocks without stressing interest coverage. This capital structure supports durable investment in automation products and opportunistic capital returns over the medium term.

OmniSphere adoption & certification

HITRUST certification and customer traction increase trust among healthcare customers, raising switching costs and platform stickiness. As a certified cloud backbone, OmniSphere can anchor recurring SaaS revenue and cross-sell connected devices, bolstering long-term competitive positioning.

Negative Factors

Low net profitability

Very low net margin (1.7%) and modest ROE constrain the firm’s ability to convert revenue growth into shareholder returns. Persistent low profitability over months suggests structural cost or pricing pressure; without margin expansion, growth may not translate into sustainable earnings improvement.

Tariff & margin headwinds

Ongoing tariff-related cost pressure is a structural headwind to gross margins and requires durable responses (pricing, sourcing, design). Continued tariff exposure over months can erode margin recovery and force trade-offs between market share and profitability.

Slower SaaS and services growth

Sluggish expansion of higher-margin SaaS and services limits the shift from hardware-driven sales to recurring revenue. If EnlivenHealth and retail-pharmacy services remain weak, the company risks extended reliance on lower-margin equipment sales, slowing margin improvement and cash conversion.

Omnicell Business Overview & Revenue Model

Company Description

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California.

How the Company Makes Money

Omnicell generates revenue through multiple streams, primarily by selling its automated dispensing systems and software solutions to healthcare providers. The company earns a significant portion of its revenue from the sale of hardware, including automated medication dispensing units and robotic systems. In addition to hardware sales, Omnicell also offers software solutions, maintenance contracts, and services that enhance the operational capabilities of its clients, creating recurring revenue through subscription and service contracts. Furthermore, strategic partnerships with healthcare organizations and technology providers contribute to its earnings by expanding market reach and integrating its solutions into existing healthcare infrastructures. The combination of these revenue streams allows Omnicell to maintain a robust financial model, driven by ongoing demand for healthcare efficiency and safety improvements.

Omnicell Financial Statement Overview

Summary

Omnicell demonstrates a stable financial position with a strong balance sheet and positive cash flow trends. Revenue and profit margins are improving, but operational efficiency remains a challenge. The company is well-positioned with low leverage, but enhancing profitability and cash flow coverage could further strengthen its financial health.

Income Statement

Omnicell's income statement shows moderate performance with a gross profit margin of 43.7% and a net profit margin of 1.7% for TTM. The company has demonstrated revenue growth of 2.5% in the TTM period, recovering from a previous decline. However, the EBIT and EBITDA margins are relatively low, indicating potential challenges in operational efficiency.

Balance Sheet

The balance sheet reflects a strong equity position with a debt-to-equity ratio of 0.16, indicating low leverage and financial stability. The return on equity is modest at 1.6%, suggesting limited profitability from shareholders' equity. The equity ratio is healthy, supporting the company's financial resilience.

Cash Flow

Omnicell's cash flow statement shows positive trends with an 8.9% growth in free cash flow. The operating cash flow to net income ratio is 0.34, and the free cash flow to net income ratio is 0.73, indicating efficient cash generation relative to net income. However, there is room for improvement in cash flow coverage.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.18B	1.11B	1.15B	1.30B	1.13B	892.21M
Gross Profit	516.04M	471.00M	499.93M	588.99M	554.65M	413.29M
EBITDA	117.75M	90.09M	79.98M	96.85M	174.44M	107.12M
Net Income	19.92M	12.53M	-20.37M	5.65M	77.85M	32.19M
Balance Sheet
Total Assets	1.95B	2.12B	2.23B	2.21B	2.14B	1.82B
Cash, Cash Equivalents and Short-Term Investments	193.45M	381.68M	467.97M	341.85M	359.72M	496.17M
Total Debt	206.78M	382.55M	614.09M	616.74M	541.01M	528.29M
Total Liabilities	727.70M	877.65M	1.04B	1.08B	995.81M	857.00M
Stockholders Equity	1.22B	1.24B	1.19B	1.13B	1.15B	967.50M
Cash Flow
Free Cash Flow	111.47M	151.26M	139.62M	17.04M	202.84M	131.00M
Operating Cash Flow	153.26M	187.72M	181.09M	77.78M	231.81M	185.87M
Investing Cash Flow	-59.51M	-52.79M	-55.02M	-58.67M	-412.50M	-279.87M
Financing Cash Flow	-461.84M	-235.58M	23.42M	-20.95M	47.36M	456.27M

Omnicell Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 48.50
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OMCL, the sentiment is Neutral. The current price of 48.5 is below the 20-day moving average (MA) of 49.54, above the 50-day MA of 44.75, and above the 200-day MA of 34.14, indicating a neutral trend. The MACD of 1.26 indicates Positive momentum. The RSI at 52.22 is Neutral, neither overbought nor oversold. The STOCH value of 20.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for OMCL.

Omnicell Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
OMCL	71 Outperform	$2.18B	113.74	1.62%	―	10.67%	―
CERT	62 Neutral	$1.40B	130.42	1.03%	―	11.47%	―
TXG	60 Neutral	$2.56B	―	-10.12%	―	1.92%	59.18%
GDRX	58 Neutral	$770.51M	26.43	4.90%	―	1.30%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
EVH	48 Neutral	$358.24M	-2.05	-13.63%	―	-16.65%	-71.92%
TDOC	47 Neutral	$967.23M	-4.26	-15.42%	―	-2.37%	77.85%

Omnicell Corporate Events

Omnicell Launches Advanced Titan XT Dispensing System

On December 8, 2025, Omnicell announced the launch of Omnicell Titan XT, an advanced automated dispensing system designed to enhance autonomous medication management. The Titan XT, powered by the cloud-based OmniSphere platform, aims to improve pharmacy control and nursing confidence by offering a connected medication management ecosystem. This innovation is expected to optimize medication inventory management and streamline nursing workflows, marking a significant milestone in Omnicell’s journey towards comprehensive healthcare automation.

The most recent analyst rating on (OMCL) stock is a Hold with a $37.00 price target. To see the full list of analyst forecasts on Omnicell stock, see the OMCL Stock Forecast page.